SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
23.19 ^CNY	+1.35%		+3.02%	-7.35%

Apr. 24	Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	MT
Apr. 18	China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	MT

Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

March 26, 2024 at 09:29 am EDT

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. proposed ordinary final dividend of RMB 0.27 per share for the year ended 31 December 2023.

Latest news about Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	Apr. 24	MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	Apr. 18	MT
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	Apr. 17	MT
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	Apr. 08	MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	Apr. 02	CI
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	Mar. 30	CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	Mar. 26	MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Mar. 25	CI
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	Mar. 14	MT
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	Mar. 08	MT
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	Mar. 07	MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	Mar. 04	MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	Feb. 29	MT
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	Feb. 20	MT
Yuyuan Tourist Mart CFO Steps Down	Feb. 05	MT
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	Jan. 25	MT
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd.	Jan. 22	CI
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets	Jan. 15	MT
Fosun Pharma Board Approves Unlocking, Vesting of Shares	Jan. 10	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited	Dec. 15	CI
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement	Dec. 11	MT
Fosun Pharmaceutical's Unit Scraps Clinical Trial on ORIN1001 Tablet	Dec. 11	MT

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Duration

Period

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

More charts

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and hospital services (10.5%); - other (0.1%). China accounts for 72.9% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.19 CNY

Average target price

29.75 CNY

Spread / Average Target

+28.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.	-7.35%	7.65B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Latest news about Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals